Tag: atrial fibrillation

Image: PD  In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Rates of Medical Errors and Preventable Adverse Events Among Hospitalized Children Following Implementation of a Resident Handoff Bundle Miscommunication during patient handoffs is a leading cause of medical errors.  In...
Image: PD In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Exdoxaban versus Warfarin in Patients with Atrial Fibrillation Factor Xa inhibitors have been shown to be noninferior to warfarin for prevention of venous thromboembolism, and dabigatran has been compared for...
Image: PD 1. The HAS-BLED score is an easy to remember and easy to apply tool that has good predictive accuracy for the risk of major bleeding in patients with atrial fibrillation 2. Since its publication, the HAS-BLED score has been validated in a large cohort study of 7,329 patients Original Date...
Classics Series, Landmark Trials in Medicine
Image: PD 1. Apixiban is superior to warfarin in preventing stroke in patients with atrial fibrillation 2. Apixaban has a decreased risk of intracranial hemorrhage compared to warfarin 3. There is no difference in GI bleeding risk between apixaban and warfarin. Original date of publication: September 15, 2011 Study Rundown: Warfarin is a vitamin...
Image: PD 1. Propofol at a dose of 1 mg/kg for hemodynamically stable patients and 0.5mg/kg in hemodynamically unstable patients appears to be a safe drug for procedural sedation in DC cardioversion of atrial tachyarrhythmias. 2. Propofol’s use in the cardioversion of ventricular tachyarrhythmias remains unknown. Evidence Rating Level: 2 (Good) Study Rundown: Propofol...
Classics Series, Landmark Trials in Medicine
1. Rate-control, along with anticoagulation, should be the main approach to managing patients with atrial fibrillation. 2. Compared to rhythm-control, rate-control resulted in a lower incidence of adverse events and no significant difference in mortality. Original Date of Publication: December 5, 2002 Study Rundown: Originally published in 2002, the Atrial Fibrillation Follow-up Investigation...
Classics Series, Landmark Trials in Medicine
Image: CC/L. academia 1. High-dose dabigatran is superior to warfarin in the prevention of strokes in patients with atrial fibrillation, while low-dose dabigatran is non-inferior to warfarin in preventing strokes in this population 2. There is lower risk of major hemorrhage on low-dose dabigatran compared to warfarin, while there is similar...
Classics Series, Landmark Trials in Medicine
1. In patients with atrial fibrillation who require anticoagulation but cannot tolerate warfarin, dual anti-platelet therapy may be a potential alternative for stroke prophylaxis. 2. Clopidogrel, in addition to daily aspirin, significantly reduced the incidence of stroke, but increased the incidence of major bleeding in patients with atrial fibrillation when...
Classics Series, Landmark Trials in Medicine
1. Rivaroxaban is non-inferior to warfarin in preventing strokes and systemic embolism. 2. Although there is no significant difference between the two in the incidence of clinically relevant bleeding, rivaroxaban is associated with significantly lower rates of critical, fatal, and intracranial bleeding. Original Date of Publication: September 8, 2011 Study Rundown: Warfarin has...
Classics Series, Landmark Trials in Medicine
1. Lenient rate-control was found to be non-inferior to strict rate-control in managing patients with atrial fibrillation. 2. Compared to strict rate-control, lenient rate-control could be achieved with lower doses of medication and fewer medications. Original Date of Publication: April 15, 2010 Study Rundown: Atrial fibrillation is the most prevalent sustained cardiac arrhythmia....